AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1. (Original) A method for treating a subject for glaucoma, comprising:

administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.

2. (Original) The method of claim 1, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

R_2 is hydrogen or alkyl;

R_3 is a single bond, alkylene, or $-(CH_2)_n-X-(CH_2)_m-$;

in which X is O, S, or N-methyl; m is 1 or 2; and n is 0, 1, or 2;

R_4 is alkyl, alkenyl, alkynyl, heterocyclyl, aryl or aralkyl; and

R_5 is alkylene, alkenylene, alkynylene and alkoxylene; and

R_6 is C_3-C_6 cycloalkyl or

$$-C\equiv CH;\text{ or}$$

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

3. (Original) The method of claim 2, wherein R_1 is a group that can be removed *in vivo*.

4. (Original) The method of claim 2, wherein R_1 is hydrogen.

5. (Original) The method of claim 2, wherein R_1 is alkyl.

6. (Original) The method of claim 5, wherein R_1 is methyl.

7. (Original) The method of claim 2, wherein R_2 is methyl.

8. (Original) The method of claim 2, wherein R_3 is methylene.

9. (Original) The method of claim 2, wherein R_4 is aryl.

10. (Original) The method of claim 2, wherein R_4 is phenyl.

11. (Original) The method of claim 2, wherein R_5 is methylene.

12. (Original) The method of claim 2, wherein R_6 is

$$—C\equiv CH.$$

13. (Original) The method of claim 2, wherein the deprenyl compound has the structure



wherein R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl.

14. (Original) The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

R_2 is hydrogen or alkyl;

R_3 is a bond or methylene; and

R_4 is aryl or aralkyl; or

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

15. (Original) The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R_2 is hydrogen or alkyl;

R_3 is a bond or methylene; and

R_4 is aryl or aralkyl; or

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group; and

R_5 is alkylene, alkenylene, alkynylene and alkoxylene;

16. (Currently Amended) The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

A is a substituent independently selected for each ~~occurence~~ occurrence from the group consisting of halogen, hydroxyl, alkyl, alkoxyl, cyano, nitro, amino, carboxyl, $-CF_3$, or azido;

n is 0 or an integer from 1 to 5;

and pharmaceutically acceptable salts thereof.

17. (Original) The method of claim 1, wherein the deprenyl compound is (-)-deprenyl.

18. (Original) The method of claim 1, wherein the deprenyl compound is (-)-pargyline.

19. (Original) The method of claim 1, wherein the deprenyl compound is (-)-desmethyldeprenyl.

20. (Cancelled)